Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BBO-8520 |
Synonyms | |
Therapy Description |
BBO-8520 inhibits KRAS G12C in both the active and inactive states, which potentially decreases downstream signaling, cell viability, and tumor growth (Cancer Res (2024) 84 (7_Supplement): ND07). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BBO-8520 | BBO8520|BBO 8520 | KRAS G12C inhibitor 34 | BBO-8520 inhibits KRAS G12C in both the active and inactive states, which potentially decreases downstream signaling, cell viability, and tumor growth (Cancer Res (2024) 84 (7_Supplement): ND07). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06343402 | Phase I | BBO-8520 BBO-8520 + Pembrolizumab | Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Recruiting | USA | AUS | 0 |